It will certainly be interesting to see how the full year report comes out. They are still waiting on FDA approval for there CollaFix. Was CE approved earlier.
This prospectus relates to the resale by the selling stockholders of up to 12,898,630 shares of our common stock, including (i) 8,215,690 shares of common stock issuable upon conversion of the principal amount of Notes and (ii) 4,682,940 shares of common stock underlying the Warrants, which were issued in connection with our Series C convertible notes financing.
You are not the only one headscratching, but atleast this makes sense with the recent bottleneck at .15.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.